Last reviewed · How we verify
NCT05798455
Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma
Phase 1, PHASE2 trial testing Sodium Pentaborate in Renal Cell Carcinoma in 30 participants. Not yet recruiting.
22 May 2025
Quick facts
| Lead sponsor | Tabriz University of Medical Sciences |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 22 May 2023 |
| Primary completion | 22 May 2025 |
| Estimated completion | 22 May 2026 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Sodium Pentaborate — full drug profile →
Conditions studied
- Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
Sponsor
Tabriz University of Medical Sciences
Who can join
18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the safety and efficacy of sodium pentaborate pentahydrate in patients with advanced renal cell carcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05798455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
Other Tabriz University of Medical Sciences trials
Trials by the same sponsor.
- NCT06840054 — The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease · Phase 2 · not yet recruiting
- NCT06809816 — Efficacy of OsteoBor in Postmenopausal Osteoporosis · Phase 2 · not yet recruiting
- NCT05700513 — Dog-rose, Cranberry Leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica and Sumac in Diabetes Mellitus · Phase 1, PHASE2 · unknown
- NCT05741606 — Safety and Efficacy of Sodium Pentaborate Pentahydrate in People With Overweight and Obesity · Phase 1, PHASE2 · unknown
- NCT05723458 — Turmeric, Black Seeds, Flaxseed and Medicago Sativa in Knee Osteoarthritis · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05798455 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tabriz University of Medical Sciences
- Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05798455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing